2021 Fiscal Year Final Research Report
Identification and application of tumor reactive T cells in hepatobiliary and pancreatic cancers to personalized cancer immunotherapy
| Project/Area Number |
18K08637
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | Teikyo University (2019-2021)
National Cancer Center Japan (2018) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中面 哲也 国立研究開発法人国立がん研究センター, 先端医療開発センター, 分野長 (30343354)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Keywords | 腫瘍浸潤T細胞 / シングル細胞解析 / 疲弊化機構 / TCR導入T細胞 / がん抗原 / ネオアンチゲン |
|---|
| Outline of Final Research Achievements |
In this project, using single-cell analysis techniques, we successfully identified and characterized tumor reactive CD8+ T cells from surgically resected specimens of hepatobiliary and pancreatic cancers. The patients with tumor reactive CD8+ T cells showed the accumulation of Ki67+ activated CD8+ T cells and the upregulation of genes related with IFNγ signaling pathway in tumor tissue, suggesting that tumor reactive CD8+ T cells isolated in vitro were also associated with immune surveillance in vivo.
We are preparing for the submission of these results. And, we try to examine anti-tumor effects by TCR-T cells with the isolated TCR genes in a patient tumor (PDX) model.
|
| Free Research Field |
がん免疫
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究成果は、免疫チェックポイント阻害療法の適応が進むがん治療において、ヒトの腫瘍に浸潤するCD8+T細胞の特徴を調べる方法論を確立し、肝細胞がん、特に非ウイルス性のがんにおいて、腫瘍応答性T細胞の特徴を明らかとした。これらの成果は、肝細胞がんにおける免疫チェックポイント併用療法の効果の理解に繋がるのみならず、自己腫瘍応答性TCR遺伝子を用いたTCR-T細胞療法の開発に繋がると期待されるする。
|
